ICON Public (NASDAQ:ICLR) issued its quarterly earnings results on Tuesday. The medical research company reported $2.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.10 by $0.02, MarketWatch Earnings reports. The company had revenue of $871.16 million during the quarter, compared to analyst estimates of $857.30 million. ICON Public had a net margin of 11.49% and a return on equity of 20.70%. ICON Public’s quarterly revenue was up 40.5% compared to the same quarter last year. During the same period last year, the business earned $1.20 EPS.
Shares of ICLR traded down $3.22 on Thursday, reaching $210.85. The company’s stock had a trading volume of 3,699 shares, compared to its average volume of 1,494,241. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $11.31 billion, a PE ratio of 33.26, a P/E/G ratio of 2.01 and a beta of 0.84. The company’s 50 day moving average price is $218.10. ICON Public has a 12-month low of $168.76 and a 12-month high of $234.22.
ICLR has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of ICON Public from a “hold” rating to a “buy” rating and set a $232.00 price objective for the company in a research note on Thursday, July 1st. Mizuho raised their price objective on shares of ICON Public from $217.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, May 3rd. Credit Suisse Group raised their price objective on shares of ICON Public from $245.00 to $250.00 and gave the company an “outperform” rating in a research note on Tuesday. Jefferies Financial Group raised their price objective on shares of ICON Public from $256.00 to $267.00 and gave the company a “buy” rating in a research note on Thursday, April 29th. Finally, Citigroup started coverage on shares of ICON Public in a research note on Wednesday, July 14th. They set a “neutral” rating and a $220.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $234.64.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Story: How to calculate the intrinsic value of a stock
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.